Cyclosporin‐A in the treatment of atopic dermatitis: effects on the immune system and clinical efficiency

Masci, S; Feliciani, Claudio; Gravante, M.; Proietto, Gianluca; Andreassi, Maria Grazia; Amatetti, Massimo; Amerio, Pierluigi

doi:10.1111/j.1468-3083.1994.tb00368.x

Cited by 1 publication

(1 citation statement)

References 19 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Masci et al . reported that several cytokines (IL‐2, IL‐1α, and IL‐1β) had disappeared from the epidermis after treatment with 5 mg/kg/day of CsA (30). In adults, Bottari et al .…”

Section: Discussionmentioning

confidence: 99%

Low‐dose cyclosporin A microemulsion in children with severe atopic dermatitis: Clinical and immunological effects

Bunikowski

Staab

Kussebi

et al. 2001

Pediatric Allergy Immunology

View full text Add to dashboard Cite

Cyclosporin A (CsA) is an effective and well-tolerated treatment for severe childhood atopic dermatitis (AD). By starting at a low dose, the therapeutic safety should be further increased. The aim of this study was to evaluate low-dose CsA in childhood AD with respect to clinical outcome and modulation of T-cell dysregulation. In an open prospective study, 10 children (age: 22-106 months) with severe AD (mean objective SCORAD score > 40 on two baseline measurements at a minimum interval of 2 weeks) were treated with CsA solution for 8 weeks. All patients received a starting dose of 2.5 mg/kg/day, which was increased stepwise in non-responders to a maximum of dose of 5 mg/kg/day. Disease activity was monitored using the SCORAD index. The frequency of cytokine-producing peripheral blood T lymphocytes was analyzed by intracellular cytokine staining, and T-cell numbers were measured by fluorescence-activated cell sorter (FACS) analysis. Twenty healthy age-matched children were included as controls for the immunological data. Nine of the 10 patients had a SCORAD reduction of at least 35%. In seven patients this was achieved with low-dose CsA at 2.5 mg/kg/day (n = 4) and 3.5 mg kg/day (n = 3). Seven of the nine responders experienced no relapse within the 4-week follow-up period. At baseline the percentage of interleukin-4 (IL-4), IL-13, and human leucocyte antigen (HLA)-DR-positive CD3(+) cells was higher in the patient group than in the controls. After CsA treatment there was a significant reduction in interferon-gamma (IFN-gamma), IL-2, IL-4, IL-13, and HLA-DR-positive CD3(+) cells. Hence, in severe pediatric AD, CsA microemulsion, when started at a low dose (2.5 mg/kg/day), improves clinical measures of disease, reduces T-lymphocyte cytokine production, and regulates T-cell activation.

show abstract

“…Masci et al . reported that several cytokines (IL‐2, IL‐1α, and IL‐1β) had disappeared from the epidermis after treatment with 5 mg/kg/day of CsA (30). In adults, Bottari et al .…”

Section: Discussionmentioning

confidence: 99%